Home > Healthcare > Medical Devices > Diagnostic Devices > Rapid Diagnostics Market

Rapid Diagnostics Market Share

Report ID: GMI5745
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Rapid Diagnostics Market Share

The market industry is characterized by the presence of several established and emerging players that offer a variety of treatments across the globe. The market players compete based on factors such as treatment quality, product innovation, regulatory compliance, customer service, and pricing strategies. Emerging companies are also gaining traction by developing advanced, user-friendly diagnostic tools. Strategic partnerships, acquisitions, and investments in R&D are common strategies used to enhance market presence and drive growth. The competitive intensity is further fuelled by the growing focus on early disease detection and personalized medicine, shaping a robust and competitive market environment.

Rapid Diagnostics Market Companies

Prominent players operating in the rapid diagnostics industry industry include:

Abbott Laboratories
ACON Laboratories Inc.
Alfa Scientific Designs Inc.
Artron Laboratories Inc.
Becton, Dickinson and Company
BioMerieux
Bio-Rad Laboratories
Danaher Corporation (HemoCue & Radiometer)
Hologic
McKesson Medical-Surgical, Inc.
Meridian Bioscience, Inc.
QIAGEN N.V.
Quidel Corporation
F. Hoffmann-La Roche Ltd.
Sight Diagnostics Ltd.
Trinity Biotech

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The rapid diagnostics industry was valued at USD 22.7 billion in 2023 and is anticipated to witness a CAGR of 9.2% through 2032, due to increasing geriatric population, along with rise in funding from government.

The infectious disease testing segment held a major market share of 25.6% in 2023, attributed to the government initiatives for early diagnostics and screening, and the development of advanced rapid tests.

North America rapid diagnostics market size was valued at USD 11.3 billion in 2023 and is predicted to record a CAGR of 8.2% through 2032, due to rising geriatric population and higher levels of healthcare expenditure.

Bio-Rad Laboratories, Danaher Corporation (HemoCue & Radiometer), Hologic, McKesson Medical-Surgical, Inc., Meridian Bioscience, Inc., QIAGEN N.V., and Quidel Corporation among others.